Ocular Drug Delivery – State-of-the-Art and New Concepts

20 - 21 June 2016, Berlin, Germany
Course no. 6639

The APV high-toned conferences are dedicated to challenging pharmaceutical topics which will be discussed in a thorough and comprehensive way from different scientific and regulatory perspectives by international best-known specialists in their area of daily work or research. These conferences are unique meeting places for networking and top-class education in one go.
SCOPE / OUTLINE:
There is an increasing interest in developing novel and improved medicines for the treatment of ocular diseases such as age-related macular degeneration (AMD), diabetic retinopathies, glaucoma, dry eye.

To enable development of new medicines not only a better understanding of the underlying disease mechanisms and the relevant targets is required, but also an in-depths understanding of the drug distribution and transport mechanisms in the eye. Novel drug delivery systems and formulation design principles play a crucial role in delivering drug molecules to targets in the front and in particular in the back of the eye. Other key aspects include the route and frequency of drug administration including controlled and extended drug release and improved patient compliance.

World leading experts from Europe and America working in preclinical and clinical R&D areas in academia, industry and CROs will provide insights to formulation related development aspects and discuss adequate approaches such as:
- Basic aspects of ocular diseases and treatment options by using modern drug delivery systems ranging from eye drops to controlled release systems
- Drug transport and pharmacokinetics in the eye
- Overview on available and novel formulations principles and drug delivery systems
- Challenges and hurdles in the development of novel drug delivery concepts including packaging
- Options for preclinical and clinical testing ocular delivery systems (CRO’s)
- Case studies

TARGET GROUP:
- Scientists, technical experts, project and line managers from various areas of ocular drug product development involved into research and development of ophthalmic drug products for new drug candidates (small and large molecules)

CONFERENCE MODERATORS:
- Professor emeritus Dr. Robert Gurny, University of Geneva, former President of the School of Pharmaceutical Sciences at the University of Geneva, Switzerland is a world leading expert in the area of ophthalmic formulations and drug delivery. His is active in the field of ocular drug delivery since more than thirty years and has co-authored over 150 papers in the field.

- Dr. Rainer Alex, has more than 25 years of experience in the area of drug product development and drug delivery research. He is currently involved into early evaluation and development activities for ophthalmic drug products in the Preclinical and Early Development unit at the Roche Innovation Center Basel at F. Hoffmann – La Roche AG in Basel.
Monday, 20 June 2016, 13:00-17:30

Welcome and Introduction, Scope of Conference
Dr. Rainer Alex
F. Hoffmann-La Roche AG, Basel, Switzerland
Prof. Robert Gurny
University of Geneva – University of Lausanne, Geneva, Switzerland

Overview on ocular diseases – Current treatment (Medical view)
Prof. Francine Behar-Cohen, Medical Director
Hôpital Ophthalmique Jules-Gonin/UNIL University of Lausanne, Switzerland

Ocular anatomy, physiology, pharmacokinetics and pK modeling
Prof. Arto Urtti, Director, Centre for Drug Research
University of Helsinki, Helsinki, Finland

Overview on available dosage forms and delivery options – from eye drops to drug delivery systems
- marketed products
- technological view
Dr. Pascal Furrer, Senior Lecturer
University of Geneva, Geneva, Switzerland

Novel drug delivery systems for ocular diseases – opportunities and challenges
Prof. Francine Behar-Cohen, Medical Director
Hôpital Ophthalmique Jules-Gonin/UNIL University of Lausanne, Switzerland

Basic aspects of formulation development and regulatory (pharmacopeia) requirements for ophthalmic products
Dr. Pascal Furrer, Senior Lecturer
University of Geneva, Geneva, Switzerland

Drug delivery to the back of the eye
Dr. Ann Daugherty, Senior Manager, Drug Delivery
Genentech Inc., San Francisco, United States

Wrap up / discussion

City tour and Networking dinner

Tuesday, 21 June 2016, 08:45-16:15

Welcome Day 2
Dr. Rainer Alex
Prof. Robert Gurny

Nanosystems
Dr. Doris Gabriel, Senior Scientist
Apidel, Geneva, Switzerland

Gene Delivery to the eye
Dr. Jean-Philippe Combal, Chief Operating Officer
GenSight, Paris, France

Novel device approaches for ocular delivery
Dr. Signe Erickson, Senior Vice President, Product Development
ForSight Vision4, San Francisco, United States

Pre-clinical in vivo (animal) testing of ocular formulations and drug delivery systems (FOTE; eye drops, subconjunctival)
Dr. Laurence Feraille, Preclinical Models Development
IRIS Pharma, La Gaude, France

Pre-clinical in vivo (animal) testing of ocular formulations and drug delivery (BOTE)-implants, ivt injections
Dr. Margaret E. Collins, Associate Director, Research Program Director, Ocular Toxicology Preclinical Services
Charles River Labs, Reno, United States

Blow-Fill-Seal technology for single and multiple dose eye drop formulations
Dr. Otto Ernst Schubert, General Manager, Director Maropack, Zell, Switzerland

New multidose dispenser for eye drops
Loïc Marchin, Founder, CEO
Pylote, Drémil-Lafage, France

Case study I: Cationic emulsions in ophthalmology: from bench to bedside
Frédéric Lallemand, Responsible research and innovation
Santen S.A.S., Evry Cedex, France

Case study II: From concept to phase 3 in eye gene therapies: Key requirements and potential strategic impact over the development phases
Dr. Jean-Philippe Combal, Chief Operating Officer
GenSight, Paris, France

Final discussion / Q&A
Location
WYNDHAM GARDEN
Berlin Mitte
Osloer Str. 1
13359 Berlin
Germany
T: +49 30 495 000-0
F: +49 30 495 000-495
E: info@wyndamgardenberlin.com

I herewith repealable authorise APV to use my E-mail address to send me APV relevant material including current programme information. My acceptance can be cancelled at any time in writing.

Ocular Drug Delivery CN 6639

Date
Course no. 6639
from 20 June 2016 to 21 June 2016
13:00 h to 16:45 h

Registration fee
APV member 1460 EUR
Non-member 1590 EUR
(free of VAT according to § 4,22 UStG)

Coffee breaks, dinner on the first day, city tour, lunch on the second day and electronic proceedings included.

Registration
As soon as you have found a seminar of your interest, it is very easy to register for it via fax, e-mail or online. We will process your registration promptly and certainly are available for any questions that may arise.

Registration confirmation
After your registration was successfully processed, you will receive a confirmation.

Before the event
A few days before the event starts, you will receive important information about the seminar, such as time, date, addresses etc.

After the event
You will receive a certificate confirming your participation. Furthermore, we would like to ask you to fill-in our evaluation sheet to make sure we get better every time.

Follow-up
After the event, we are open to receive any suggestions and critique that might arise during the seminar and will certainly help you with further questions you may have.

Order No. or Billing Address

APV Member  
Non-Member

Date
Signature

*Mandatory

Title, First Name, Last Name *
Company Name *
Company Address *
Location *
Zip-Code *
Phone *
Department *
E-mail Address Participant *
Order No. or Billing Address

pay via invoice
pay via credit card (fill in below)

AMEX
Visa
Mastercard

Card Holder
Card No.
Valid until
CVC Code

Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V.
Gemeinnütziger wissenschaftlicher Verein
International Association for Pharmaceutical Technology
www.apv-mainz.de

Participants should make their own hotel reservation referring to the APV seminar.
Deadline for special conference rate: 25 May 2016.
Special rate:
Single room incl. breakfast buffet from 89 EUR per night.

Mainz, March 2016